Resistance mechanisms to taxanes and PARP inhibitors in advanced prostate cancer

Alan P. Lombard, Allen C. Gao

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


The clinical landscape concerning advanced prostate cancer is rapidly changing and reaching beyond androgen deprivation therapy and androgen receptor-targeted therapies. Taxane chemotherapy is a critical tool in the management of advanced prostate cancer. Additionally, novel drug classes, such as PARP inhibitors, are being investigated. In spite of the tremendous progress, resistance to therapy remains as a major impediment to further improvement. Resistance mechanisms appear diverse and are not fully known or understood. This review will highlight recent advances in research regarding mechanisms of resistance to both taxanes (such as increased drug efflux capacity) and PARP inhibitors (such as reversion mutations, which restore DNA-repair proficiency). Understanding resistance to therapy promises to remove barriers blocking progress toward improved patient outcomes.

Original languageEnglish (US)
Pages (from-to)16-22
Number of pages7
JournalCurrent Opinion in Endocrine and Metabolic Research
StatePublished - Feb 2020


  • Cabazitaxel
  • Docetaxel
  • Olaparib
  • PARP inhibitor
  • Resistance
  • Taxane

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Resistance mechanisms to taxanes and PARP inhibitors in advanced prostate cancer'. Together they form a unique fingerprint.

Cite this